高剂量率近距离治疗作为局限性前列腺癌单一疗法的长期随访结果
研究纳入2004年3月至2008年1月接受高剂量率近距离治疗(HDR-BRT)单一疗法的351例临床局限性前列腺癌患者,采用两次植入、间隔14天、每次9.5 Gy分两次的方案。中位随访158个月时,201例可分析,60、120、158个月生化控制率分别为94%、90%、86%,无转移生存率分别为97%、89%、83%,晚期2-3级下尿路症状发生率3.9%,晚期3级胃肠道毒性2%,无4级及以上毒性。结论认为HDR-BRT是器官局限前列腺癌安全有效的单一疗法。
要点
- HDR-BRT单一疗法两次植入间隔14天,每次9.5 Gy分两次,中位随访158个月。
- 158个月生化控制率86%,无转移生存率83%。
- 晚期2-3级下尿路症状3.9%,晚期3级胃肠道毒性2%,无4级及以上毒性。
核心结论
- HDR-BRT是器官局限前列腺癌安全有效的单一疗法。
研究设计与样本
- 单中心连续351例临床局限性前列腺癌患者接受HDR-BRT单一疗法,两次植入间隔14天,每次9.5 Gy分两次。
- 中位随访158个月,201例符合分析条件,62例死亡,150例失访。
主要发现
- 60、120、158个月生化控制率分别为94%、90%、86%。
- 60、120、158个月无转移生存率分别为97%、89%、83%。
- 8例(3.9%)出现晚期2-3级下尿路症状,表现为尿急和尿频增加,无大于2级排尿困难或尿失禁。
- 4例(2%)出现晚期3级胃肠道毒性。
- 无4级或以上急性或晚期毒性发生。
临床怎么用
- 对于临床局限性前列腺癌,可考虑HDR-BRT单一疗法作为治疗选择。
局限性
- 初始队列351例中150例失访,仅201例可分析。
- 随访期间62例死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To report the clinical outcome of High-Dose-Rate (HDR) brachytherapy (BRT) as sole treatment for clinically localised prostate cancer (PCA). METHODS: From March 2004 to January 2008, 351 consecutive patients with clinically localised PCA were treated with HDR monotherapy receiving two BRT implants, separated by 14 days, each delivering two fractions at 9.5 Gy to an intraoperative transrectal ultrasound real-time defined planning treatment volume. The present report describes the updated long-term results of this two-implant protocol. Biochemical relapse was defined according to the Phoenix definition and toxicity evaluated using the Common Toxicity Criteria for Adverse Events version 3. RESULTS: The median follow-up for the current analysis was 158 months with 201 patients eligible for analysis. Out of the initial cohort, 62 patients died during follow-up and 150 were lost to follow-up. The 60-, 120- and 158-months biochemical control and metastasis-free survival rates were 94%, 90%, 86% and 97%, 89%, 83%, respectively. Eight (3.9%) patients developed late Grade 2-3 lower urinary tract symptoms characterized by increased urgency and frequency with no dysuria or incontinence > Grade 2. Four (2%) patients developed late Grade 3 gastrointestinal toxicity. No Grade 4 or higher acute or late toxicities occurred. CONCLUSIONS: Our results confirm HDR-BRT to be a safe and effective monotherapy for organ-confined PCA.
引用
- Best C, Spier V, Baltas D, et al. High-dose-rate monotherapy for localised prostate Cancer: A two-implant approach with median 13 years follow-up. Clin Transl Radiat Oncol. 2026. PMID: 42656843. doi:10.1016/j.ctro.2026.101228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。